News &amp; Updates

Various studies have shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring system for the continuous monitoring of glucose levels in type 1 and type 2 diabetes (T1D and T2D) patients. While clinical trials have demonstrated a reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and significant reduction in glycated haemoglobin (HbA1c), real-world data have shown improved glycaemic control in these patients.

Clinical benefits of flash glucose monitoring with FreeStyle Libre™

Exercise programme sustains normal heart rate in AF patients

Six months of combined supervised exercise training and home-based physical activity helps to prevent atrial fibrillation (AF) recurrence and severity of symptoms in patients with persistent AF, according to the ACTIVE-AF* study presented at ESC 2021.

Exercise programme sustains normal heart rate in AF patients

Imatinib significantly reduces proinflammatory cytokines in SARS-CoV-2–affected endothelial cells

Researchers from The University of Hong Kong (HKU) have uncovered a novel mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–induced lung injury and vascular damage through epithelial–endothelial cell interaction and demonstrated the immunomodulatory role of imatinib, supporting its use for the treatment of coronavirus-19 (COVID-19).

Imatinib significantly reduces proinflammatory cytokines in SARS-CoV-2–affected endothelial cells

CLAM in R/R AML: High response rates, effective bridge to allo-HSCT

One cycle of clofarabine, cytarabine and mitoxantrone (CLAM) achieves an overall response rate (ORR) of >90 percent with a complete remission (CR) rate of nearly 70 percent in a phase II study of Hong Kong patients with refractory/relapsed acute myeloid leukaemia (R/R AML).

CLAM in R/R AML: High response rates, effective bridge to allo-HSCT

Simeprevir potently suppresses SARS-CoV-2 replication, shows synergy with remdesivir

An international study led by researchers from The Chinese University of Hong Kong (CUHK) and The University of Hong Kong (HKU) finds that protease inhibitor simeprevir potently reduces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and demonstrates synergy with remdesivir in vitro.

Simeprevir potently suppresses SARS-CoV-2 replication, shows synergy with remdesivir

Air pollution strongly correlated with atherogenesis; intervention study planned

A study by the Chinese University of Hong Kong (CUHK) and Chongqing Medical University finds a strong association between air pollution and markers of early atherosclerosis, suggesting a potential target for preventive intervention.

Air pollution strongly correlated with atherogenesis; intervention study planned

CUHK researchers discover a mutation prognostic of prolonged survival in SCCHN

Researchers from the Chinese University of Hong Kong (CUHK) have discovered a novel genetic biomarker associated with extended survival in head and neck squamous cell carcinoma (HNSCC), which is found in almost 20 percent of HNSCC tumours.

CUHK researchers discover a mutation prognostic of prolonged survival in SCCHN

Benign prostatic hyperplasia on the rise, surgical interventions declining

There seems to be an increasing trend in the diagnosis rate of benign prostatic hyperplasia (BPH), accompanied by a gradual rise in medical treatment and decline in surgical interventions, a new South Korea study has shown.

Benign prostatic hyperplasia on the rise, surgical interventions declining

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

14 Sep 2021 by

The potassium-competitive acid blocker vonoprazan appears to be more effective than proton pump inhibitors (PPIs) in healing severe erosive esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD), according to a meta-analysis presented at APDW 2021.

Vonoprazan bests PPIs in relieving GERD symptoms in latest meta-analysis

SGLT inhibitors prevent AF events, cardiac hospitalization, death

14 Sep 2021 by

Sodium‐glucose co‐transporter (SGLT) inhibitors appear to protect against the development or recurrence of atrial fibrillation (AF), as well as the reduce heart failure (HF) hospitalization or cardiovascular death in type 2 diabetes mellitus (T2DM) patients with or without AF, according to a recent meta-analysis.

SGLT inhibitors prevent AF events, cardiac hospitalization, death